RxDoctor Payments Data

Samuel Steerman, MD

Vascular Surgery · Virginia Beach, VANPI 1639349335

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 57.9% of the total. Reporting peaked in 2021 at $65,657 and has fallen 84.4% since, to $10,267 in 2025. Among vascular surgery clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$252,233in general payments, 2019–2025

Across 569 payments — averaging $443.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$146K
  • Medtronic$55K
  • Abbott$32K
  • Endologix LLC$7K
  • Philips North America LLC$2K
  • Inari Medical, Inc.$1K
  • plus $9K from 22 others
$77,679in research payments, 2019–2025

Across 24 payments — averaging $3236.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$43K
  • M.a. Med Alliance S.A.$22K
  • Merit Medical Systems Inc$13K

What the payments were for

  • Consulting fees$128,53151%
  • Speaking & faculty fees$82,72533%
  • Travel & lodging$14,4406%
  • Food & beverage$26,53711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$252,233 in reported general payments places this provider in the 95th percentile of 143 vascular surgery providers in Virginia.

See all vascular surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$631,012
Medicare patients
2,636
Services billed
4,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$17,360
XareltoRivaroxaban19$13,903
ClopidogrelClopidogrel Bisulfate94$480
Cilostazol19$224
Simvastatin26$143
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen25$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$97$13,90319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 vascular surgery providers in Virginia.

Other vascular surgery in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →